Traditional Chinese medicine composition for treating diarrhea-type irritable bowel syndrome as well as preparation method and application of traditional Chinese medicine composition
By using traditional Chinese medicine combinations to warm and unblock the meridians and soothe the liver and strengthen the spleen, the treatment challenges of diarrhea-predominant irritable bowel syndrome have been solved, improving patients' symptoms and quality of life, and providing a safe and effective treatment option.
Patent Information
- Application Number
- CN202410918711.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current technologies lack precise and effective drug treatment options. Western medicine has little effect on diarrhea-predominant irritable bowel syndrome (IBS-D). Traditional Chinese medicine treatment faces challenges in evaluation and comparative efficacy studies. Furthermore, psychological factors play an important role in the occurrence and development of IBS, leading to a decline in patients' quality of life.
A traditional Chinese medicine composition is provided, which is composed of cinnamon twig, turmeric, atractylodes macrocephala, dried ginger, cinnamon bark, fennel, poria cocos, pinellia ternata, tangerine peel, evodia rutaecarpa, hawthorn, costus root, licorice, etc. It is prepared into decoction, oral liquid, granules, capsules, tablets and other forms for treatment by warming and unblocking the meridians, soothing the liver and strengthening the spleen, regulating qi and relieving pain.
It significantly improves the symptoms of diarrhea-predominant irritable bowel syndrome, reduces TCM syndrome scores and irritable bowel syndrome severity scores, improves patients' quality of life, and has good safety profile.
Smart Images

Figure CN118976086A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a traditional Chinese medicine composition for treating diarrhea-type irritable bowel syndrome and a preparation method and application thereof, belonging to the field of traditional Chinese medicine. Background Art
[0002] Irritable bowel syndrome (IBS) is one of the common digestive tract diseases in clinical practice. Its main clinical symptoms are abdominal pain or abdominal discomfort accompanied by changes in bowel habits and (or) abnormal stool characteristics. It is a functional intestinal disease, which is divided into constipation type (IBS-C), diarrhea type (IBS-D), mixed type (IBS-M) and uncertain type (IBS-U), among which diarrhea type (IBS-D) is the most common. In recent years, the incidence of IBS has continued to increase. Due to its long-term persistence and repeated attacks, it has caused disorders in the patient's physical state, mental state, and psychology, seriously affecting the quality of life. IBS is a psychosomatic disease caused by the combined action of multiple factors that cause abnormal brain-gut interaction. Its pathogenesis involves multiple factors such as visceral hypersensitivity, gastrointestinal motility abnormalities, intestinal microecological imbalance, immune-neural activation, and mental and psychological disorders. Mental and psychological factors play an important role in the occurrence and development of IBS. Negative mental and psychological factors induce and promote the occurrence and development of IBS, and the repeated attacks of IBS symptoms aggravate the patient's negative emotions. Previous studies have found that most IBS patients have varying degrees of anxiety, depression, tension, insomnia and other mental disorders. For such patients, drug treatment alone is often ineffective, and symptoms are prone to recurrence, forming a vicious cycle with negative emotions, which seriously affects the quality of life of patients. The pathogenesis of irritable bowel syndrome is still unclear, and there is no clear organic lesion as a basis for diagnosis in clinical practice. Therefore, clinical diagnosis is mostly based on gastrointestinal symptoms and lacks the support of corresponding auxiliary examination results. In terms of treatment, Western medicine mainly focuses on symptomatic treatment, but lacks accurate and effective drug treatment. Although it has a certain effect on improving short-term symptoms, it has little effect on long-term prognosis.
[0003] Clinical research on the treatment of IBS-D with traditional Chinese medicine faces challenges in design, implementation, and effect evaluation. How to scientifically evaluate the efficacy of traditional Chinese medicine and how to conduct comparative effect studies between different treatments are issues that need to be addressed in current research (Chen Min, et al. Current status and thinking on comparative effect studies of traditional Chinese medicine in the treatment of diarrhea-type irritable bowel syndrome. Chinese General Practice [J], 2022, 25(15):1795-1800, F01 doi:10.12114 / j.issn.1007-9572.2022.02.008). According to the main clinical manifestations of IBS, the TCM disease name belongs to the categories of "diarrhea" and "abdominal pain". Patients with abdominal pain and abdominal discomfort as the main symptoms should belong to the category of "abdominal pain"; patients with clear stool as the main symptom should belong to the category of "diarrhea". The pathogenesis of IBS is mostly due to congenital deficiency and / or acquired malnutrition. Emotional disorders, improper diet, and exposure to external pathogens are the main causes of the disease. Wang Kentang once said: "(Dai Fu'an) diarrhea is caused by the indigestion of food and water, which is caused by dampness and wind." He believed that diarrhea is often related to wind and rheumatism. "Suwen·Jutonglun" said: "Cold invades the small intestine, and the small intestine cannot gather, so diarrhea and abdominal pain occur later." That is, the invasion of cold evil can cause abdominal pain and diarrhea. Therefore, the location of IBS is in the intestine, mainly involving the liver, spleen, stomach, kidney and other internal organs, and also has a certain relationship with the lungs and heart. Summary of the invention
[0004] The inventor has concluded in long-term clinical practice that spleen and stomach weakness and (or) liver dysfunction are important links in the onset of IBS, liver depression and spleen deficiency are important pathogenesis leading to IBS, and spleen and kidney yang deficiency and mixed deficiency and excess are key factors leading to the protracted and difficult-to-cure disease. The present invention provides a Chinese medicine composition for treating diarrhea-type irritable bowel syndrome. The present invention also provides a preparation method and use of the Chinese medicine composition.
[0005] The present invention provides a traditional Chinese medicine composition for treating diarrhea-type irritable bowel syndrome, which is a preparation prepared from the following raw materials in weight proportion:
[0006] 6-20 parts of cinnamon twig, 10-24 parts of curcuma, 6-25 parts of atractylodes, 6-25 parts of dried ginger, 6-21 parts of cinnamon, 12-22 parts of fennel, 10-20 parts of poria, 3-25 parts of pinellia, 6-20 parts of tangerine peel, 10-25 parts of evodia rutaecarpa, 12-24 parts of hawthorn, 12-20 parts of magnolia officinalis, and 3-10 parts of licorice.
[0007] Furthermore, it is a preparation prepared from the following raw materials in the following weight ratio:
[0008] 12-18 parts of cinnamon twigs, 12-18 parts of curcuma, 12-18 parts of atractylodes, 12-18 parts of dried ginger, 8-12 parts of cinnamon, 12-18 parts of fennel, 12-18 parts of poria, 12-18 parts of pinellia, 12-18 parts of tangerine peel, 8-12 parts of evodia rutaecarpa, 16-24 parts of hawthorn, 8-12 parts of magnolia officinalis, and 8-12 parts of liquorice.
[0009] Furthermore, it is a preparation prepared from the following raw materials in the following weight ratio:
[0010] 15 parts of cinnamon twigs, 15 parts of curcuma, 15 parts of atractylodes, 15 parts of dried ginger, 10 parts of cinnamon bark, 15 parts of fennel, 15 parts of poria, 15 parts of pinellia, 15 parts of tangerine peel, 10 parts of evodia rutaecarpa, 20 parts of hawthorn, 10 parts of magnolia officinalis, and 10 parts of liquorice.
[0011] Among them, the pinellia is French pinellia; the hawthorn is raw hawthorn; and the licorice is roasted licorice.
[0012] The Chinese medicine composition of the present invention is prepared from the raw powder of the raw medicine in the weight ratio, water or organic solvent extract as active ingredients, and pharmaceutically acceptable excipients or auxiliary ingredients to form a commonly used oral preparation in medicine.
[0013] Among them, the oral preparations are decoctions, oral liquids, granules, capsules, tablets, and powders.
[0014] The present invention provides a method for preparing the Chinese medicine composition for treating diarrhea-type irritable bowel syndrome, which comprises the following steps:
[0015] (1) Weigh each API according to the weight ratio;
[0016] (2) The raw material drug is directly powdered, or the raw material drug is decocted with water or extracted with an organic solvent, the extract is concentrated, and then pharmaceutically acceptable excipients are added to prepare a preparation.
[0017] The invention provides use of the traditional Chinese medicine composition in preparing a medicine for treating diarrhea-type irritable bowel syndrome.
[0018] The invention provides use of the traditional Chinese medicine composition in preparing medicine for treating diarrhea caused by liver depression and spleen deficiency syndrome.
[0019] Among them, the medicine is a medicine with the functions of supporting yang, warming the body, soothing the liver and strengthening the spleen.
[0020] Clinical summary found that cinnamon twig, curcuma, atractylodes, French pinellia, dried orange peel, poria, dried ginger, cinnamon, fennel, evodia, raw hawthorn, magnolia officinalis, and roasted licorice are effective in treating diarrhea-type irritable bowel syndrome. Cinnamon twig is the tender branch of Cinnamomum cassia Presl., a plant of Lauraceae. It is pungent and warm, and enters the heart, lung, and bladder meridians. It has the effects of sweating and relieving muscles, warming and unblocking meridians, and assisting yang and transforming qi. Atractylodes is the dried rhizome of Atractylodes macrocephala Koidz., a plant of Asteraceae. It has the effects of strengthening the spleen and replenishing qi, drying dampness and promoting diuresis. "Famous Doctors' Records" says that Atractylodes: "eliminating phlegm and water, expelling wind and water swelling between the skin, eliminating the urgent fullness under the heart, and cholera vomiting and diarrhea... benefiting body fluids, warming the stomach, digesting food and eating more", and Li Gao also called it "removing dampness in various meridians and regulating the spleen and stomach". It is clinically used to treat spleen deficiency, poor appetite, abdominal distension, diarrhea, edema, etc. Curcuma is pungent, bitter, cold, and enters the heart, liver, and lung meridians. It can promote qi and dissipate blood stasis, clear the heart and relieve depression. It is mainly used to treat amenorrhea, dysmenorrhea, and chest and abdominal pain. The "Compendium of Materia Medica" says that Curcuma: "It can treat depression and cannot be dispersed." The "Compendium of Materia Medica" also says that it: "It can promote qi and relieve depression; it can relieve blood and break blood stasis. It can cool the heart and disperse liver depression." It is used together as the main medicine to warm the yang, warm the circulation, and soothe the liver and strengthen the spleen. Ganjiang warms the middle and dispels cold. It is recorded in the "Famous Doctors' Records" that it "treats cold abdominal pain, nausea, cholera, and fullness." The "Rihuazi Materia Medica" also points out that it: "It can eliminate phlegm and reduce qi, treat convulsions, vomiting and diarrhea, cold in the abdomen, and nausea and retching." Cinnamon bark can dispel cold and relieve pain, warm the meridians and dredge the blood vessels. It is recorded in the "Famous Doctors' Records" that it "warms the middle, benefits the liver and lung qi, treats cold and heat in the heart and abdomen, cold diseases, and cholera cramps". The "Origin of Medicine" says that it "replenishes the deficiency of the lower jiao, treats deep cold and cold shoulders, and spontaneous sweating due to superficial deficiency". It is pungent and sweet, very hot, and enters the kidney, spleen, heart, and liver meridians. It can replenish fire and yang, dispel cold and relieve pain, promote blood circulation and dredge the meridians. It can be used for cold pain in the heart and abdomen, vomiting and diarrhea due to deficiency and cold, etc. Fennel is pungent and warm, warms the kidney and liver, dispels cold and relieves pain, regulates qi and harmonizes the stomach, and is mainly used to treat abdominal pain caused by cold hernia, testicular prolapse, cold pain in the abdomen, and vomiting and diarrhea due to loss of appetite. Poria cocos strengthens the spleen and eliminates dampness, calms the mind and soothes the nerves. The "Shennong's Herbal Classic" records that Poria cocos "treats chest and flank reversal of qi, worry, anger, shock, evil fear, palpitations, heart knot pain... and promotes urination". It tastes sweet and flat, and mainly enters the heart and spleen meridians. It can penetrate dampness and promote water, benefit the spleen and stomach, and calm the mind and soothe the nerves. All of the above medicines are ministerial medicines, which help the monarch medicine to warm and strengthen the spleen. Banxia is a processed product of Banxia, which is pungent and warm, and enters the spleen, stomach, and lung meridians. It has the effects of drying dampness and resolving phlegm, eliminating lumps and dispersing lumps, and is used for cough with phlegm, phlegm and fluid, and palpitations. Tangerine peel is bitter, pungent, and warm, and enters the lung and spleen meridians. "Compendium of Materia Medica" says: "Pungent can disperse, bitter can dry, and can purge... It is a medicine for spleen and lung qi (the spleen is the mother of qi, and the lung is the qi. All tonic and astringent medicines must be supplemented with tangerine peel to benefit qi)", which has the effects of regulating qi and strengthening the spleen, drying dampness and resolving phlegm. Banxia and tangerine peel are used together as adjuvants, which play the effects of strengthening the spleen and drying dampness, regulating qi and eliminating lumps, and are adjuvants. Hawthorn is sour, sweet and warm, and enters the spleen, liver and stomach meridians. "Compendium of Materia Medica" says: "It can digest food, eliminate meat accumulation, treat abdominal masses, phlegm and fluid distension, acid reflux, and blood stasis and pain." It can digest food, strengthen the stomach, promote qi and disperse blood stasis. It is mainly used to treat meat stagnation, gastric bloating, diarrhea and abdominal pain.Muxiang is pungent, bitter and warm. It is good at promoting qi and relieving pain, strengthening the spleen and digesting food. "Rihuazi Bencao" says it: "It can treat all kinds of qi in the heart and abdomen, stop diarrhea, cholera, dysentery, stabilize pregnancy, and strengthen the spleen and digest food." Evodia rutaecarpa warms the middle and relieves pain, regulates qi and dries dampness. The three medicines can be used together to strengthen the spleen and digest food, promote qi and relieve pain. It is also an adjuvant for abdominal distension and abdominal pain in diarrhea-type irritable bowel syndrome. Licorice is roasted and used to treat spleen and stomach weakness, poor appetite, abdominal pain and loose stools. As "Yao Xing Lun" says, "It can treat cold pain in the abdomen... eliminate abdominal distension; nourish the five internal organs; and control the toxicity of various drugs." It can not only strengthen the spleen-strengthening effect of the above drugs, but also harmonize the drugs and serve as an adjuvant.
[0021] In summary, in the raw material drug formula of the present invention, cinnamon twig warms and unblocks the meridians, assists yang and transforms qi, white atractylodes invigorates qi and strengthens the spleen, dries dampness and promotes diuresis, and turmeric soothes the liver and relieves depression, promotes qi and activates blood circulation to relieve pain, and is used together as the main drug, playing the role of warming and supporting yang, warming and unblocking, soothing the liver and strengthening the spleen. Dry ginger warms the middle and dispels cold, cinnamon dispels cold and relieves pain, warms the meridians and unblocks the meridians, fennel dispels cold and relieves pain, regulates qi and harmonizes the stomach, and tuckahoe invigorates the spleen and eliminates dampness, calms the mind and calms the nerves, and helps the main drug warm and unblock the spleen as the minister drug. French pinellia ternata dries dampness and resolves phlegm, eliminates lumps and resolves knots, and tangerine peel regulates qi and strengthens the spleen, dries dampness and resolves phlegm, and the two are used together as adjuvants, playing the role of regulating qi, drying dampness and resolving phlegm. Guangmuxiang promotes qi and relieves pain, Evodia rutaecarpa warms the middle and relieves pain, regulates qi and dries dampness, and raw hawthorn promotes blood circulation and removes blood stasis, digests food and resolves accumulation, and serves as an adjuvant. Roasted licorice invigorates the spleen and replenishes qi, and harmonizes various drugs, and is also an adjuvant. The whole formula has the functions of supporting yang, warming the body, soothing the liver and strengthening the spleen. It has a good effect in treating diarrhea-type irritable bowel syndrome.
[0022] Clinical and animal experimental results show that the Chinese medicine composition of the present invention has a precise formula and can effectively treat diarrhea-type irritable bowel syndrome, providing an option for clinical treatment of diarrhea-type irritable bowel syndrome and having good application prospects.
[0023] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0024] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 Comparison of HE staining of colon tissues of rats in each group (×200)
[0026] Figure 2 Comparison of AB-PAS staining of colon tissues of rats in each group (×100) DETAILED DESCRIPTION
[0027] Example 1. Preparation of the pharmaceutical composition of the present invention
[0028] Prescription: 15g cinnamon twig, 15g turmeric, 15g atractylodes, 15g dried ginger, 10g cinnamon, 15g fennel, 15g poria, 15g pinellia, 15g tangerine peel, 10g evodia, 20g raw hawthorn, 10g magnolia officinalis, and 10g roasted licorice.
[0029] Preparation method: Weigh the raw materials according to the above prescription ratio and put them into a casserole, add 2500ml of water, soak for half an hour, boil over high heat, and then simmer over low heat until 200±20ml is left, pour the boiled liquid into a bowl, add 1500ml of water to the residue, boil over high heat first, and then simmer over low heat until 200±20ml is left, pour the boiled liquid into a bowl, mix the two liquids evenly and take.
[0030] Example 2: Preparation of the pharmaceutical composition of the present invention
[0031] Prescription: 6g of cinnamon twig, 10g of turmeric, 6g of white atractylodes, 6g of dried ginger, 6g of cinnamon, 12g of fennel, 10g of poria, 3g of pinellia, 6g of tangerine peel, 10g of evodia rutaecarpa, 12g of raw hawthorn, 12g of magnolia officinalis, and 3g of roasted licorice.
[0032] Preparation method: Same as Example 1.
[0033] Example 3. Preparation of the pharmaceutical composition of the present invention
[0034] Prescription: 18g cinnamon twig, 20g turmeric, 25g atractylodes, 22g dried ginger, 16g cinnamon, 22g fennel, 20g poria, 18g pinellia, 18g tangerine peel, 20g evodia, 24g raw hawthorn, 20g magnolia officinalis, and 10g roasted licorice.
[0035] Preparation method: Same as Example 1.
[0036] The beneficial effects of the pharmaceutical composition of the present invention are illustrated below by using Research Examples 1 and 2.
[0037] Experimental Example 1: Clinical study on the treatment of diarrhea-type irritable bowel syndrome with the pharmaceutical composition of Example 1 of the present invention
[0038] 1. Case data
[0039] A total of 90 patients with diarrhea-predominant irritable bowel syndrome were included, including 41 males and 49 females, aged 18 to 60 years old. The patients were randomly divided into 2 groups: 42 cases in the control group and 48 cases in the experimental group. There were no significant differences in gender, age, TCM syndrome score before treatment, irritable bowel syndrome severity (IBS·SSS) score scale, and quality of life scale (IBS·QOL) between the two groups (P>0.05), and the two groups were comparable.
[0040] 2. Diagnosis and inclusion criteria
[0041] 2.1 Western medicine diagnostic criteria
[0042] Meet the Rome IV diagnostic criteria for functional gastrointestinal disorders published in 2016: Abdominal discomfort or pain persists for more than half a year and in the past three months, with symptoms occurring at least three days a month, and accompanied by at least two of the following characteristics: ① Symptoms improve after defecation; ② Symptoms occur with changes in the frequency of bowel movements. ③ Symptoms occur with changes in stool characteristics. Diarrhea type should have: ① At least 25% of bowel movements are loose (mushy) or watery stools, and hard or dry stools are less than 25%; ② Accompanied by mild to moderate anxiety and depression status assessment; ③ No other related treatments have been received within 1 week before participating in this study.
[0043] 2.2 TCM diagnostic criteria
[0044] Liver depression and spleen deficiency syndrome meets the syndrome differentiation criteria of "Expert Consensus on TCM Diagnosis and Treatment of Irritable Bowel Syndrome (2017)":
[0045] Main symptoms: ① Abdominal pain and urge to diarrhea, pain relieved after diarrhea; ② Depression or irritability.
[0046] Secondary symptoms: ① pain and distension in the flanks; ② poor appetite; ③ frequent belching and sighing; ④ mental fatigue.
[0047] The diagnosis can be confirmed by combining the main symptom ① + 3 secondary symptoms, or 2 main symptoms + 2 secondary symptoms, with tongue and pulse (pale tongue with thin white or greasy fur, stringy or thin pulse).
[0048] 2.3 Inclusion criteria
[0049] Only those who met the following conditions at the same time could be included in the study: (1) met the diagnostic criteria in 1.1 and 1.2; (2) had not taken any medication that may affect intestinal function, pain, or psychiatric drugs in the past month; (3) were aged 18-60 years, regardless of gender; and (4) had informed consent and signed the informed consent form.
[0050] 2.4 Exclusion criteria
[0051] Patients who met any of the following conditions were excluded from the study: (1) constipation-predominant irritable bowel syndrome, mixed irritable bowel syndrome, amorphous irritable bowel syndrome, other diseases that cause diarrhea, such as gastrointestinal infectious diseases or ulcerative diseases; (2) the presence of digestive tumors or severe organic diseases; (3) cognitive impairment and inability to cooperate or poor compliance and refusal to cooperate; (4) currently participating in other clinical trials; (5) allergic to the drugs in this study; (6) taking drugs that may affect intestinal function, pain, or mental health in the past month; (7) pregnant or lactating women; (8) patients with severe mental illness, inflammatory bowel disease, or severe heart, liver, kidney, or cerebrovascular diseases; (9) refusal of traditional Chinese medicine treatment; (10) patients who are unable or unwilling to sign the informed consent form.
[0052] 3. Treatment Methods
[0053] (1) Administration method: All 48 patients in the test group orally took the medicine prepared in Example 1. Administration method: Each dose of the medicine prepared by the composition of the present invention is a daily dose, which is taken orally three times. All 42 patients in the control group used Bifidobacterium tetravalent viable tablets (National Medicine Standard No. S20060010, Hangzhou Yuanda Biopharmaceutical Co., Ltd.), orally, 3 times a day, 3 tablets per time. The treatment course is 2 weeks.
[0054] (2) Precautions: Advise the patient to regulate his emotions, control his diet, and avoid wind and cold.
[0055] 4. Observation indicators
[0056] (1) TCM syndrome scoring
[0057] TCM syndrome scoring standard
[0058]
[0059] (2) The severity of the disease was assessed using the IBS-SSS scoring scale. The abdominal pain frequency score was calculated as follows: abdominal pain frequency score = actual number of days with abdominal pain in every 10 days × 10. The degree of abdominal pain, degree of abdominal distension, bowel satisfaction, and impact on life were assessed using the visual analog scale, with each item ranging from 0 to 100 points, with a total score of 500 points. 0-75 points were grade I, i.e. healthy; 76-175 points were grade II, i.e. mild; 176-300 points were grade III, i.e. moderate; >300 points were grade IV, i.e. severe.
[0060] (3) Quality of life: The Intensive Broad-Based Life Scale (IBS·QOL) was used to assess quality of life, which consists of 8 domains and 34 related items. The higher the score, the better the patient's quality of life.
[0061] (4) Efficacy evaluation: (1) cured, symptoms disappeared, TCM syndrome score decreased by ≥95%; (2) markedly effective, symptoms significantly improved, TCM syndrome score decreased by ≥70% but <95%; (3) effective, symptoms improved, TCM syndrome score decreased by ≥30% but <70%; (4) ineffective, symptoms not improved, TCM syndrome score decreased by <30%. Total effective rate = (number of clinically cured cases + number of markedly effective cases + number of effective cases) / total number of cases × 100%.
[0062] (5) Safety indicators During the treatment, possible adverse reactions in the two groups were recorded, and three major routine indicators and liver and kidney function indicators were tested.
[0063] 5. Statistical methods
[0064] SPSS 25.0 statistical analysis software was used. Measurement data were expressed as (x±s), and t-test was used for comparison between groups; count data were expressed as percentages, and chi-square test was used for comparison between groups; rank data were compared between groups using rank sum test. P<0.05 indicated statistically significant differences.
[0065] 6. Treatment Outcomes
[0066] 6.1 TCM symptom efficacy
[0067] After treatment, the efficacy of TCM symptoms in the experimental group was significantly better than that in the control group, and the difference was statistically significant (P < 0.01). See Table 1 for details.
[0068] Table 1 Comparison of TCM syndrome efficacy between the two groups of patients after treatment (case %)
[0069] Group Number of cases get well Significant effect efficient invalid Total Effectiveness Control group 22 0 5 15 2 90.9 Experimental Group 23 1 14 8 0 <![CDATA[100.0 * ]]>
[0070] Note: Compared with the control group, *p<0.05.
[0071] 6.2 Irritable bowel syndrome severity (IBS·SSS) score
[0072] After treatment, the IBS·SSS scores of the control group and the experimental group were lower than before, and the difference was statistically significant (P < 0.05). Compared with the control group, the IBS·SSS scores of the experimental group were significantly lower than those of the control group, and the differences were statistically significant (P < 0.05). See Table 2 for details.
[0073] Table 2 Comparison of IBS·SSS scores between the two groups after treatment (points, x±s)
[0074]
[0075] Note: Compared with the group before treatment, #p<0.05; compared with the control group during the same period, * p<0.05.
[0076] 6.3 Safety evaluation
[0077] No serious adverse reactions were found in either the experimental or control group, and no abnormalities were found in routine blood tests, stool tests, urine tests, and liver and kidney function indicators.
[0078] The composition of the present invention can effectively treat diarrhea-type irritable bowel syndrome and has good safety.
[0079] Experimental Example 2: Animal experiment on treating diarrhea-type irritable bowel syndrome in rats with the pharmaceutical composition of Example 1 of the present invention
[0080] 1. Animal Grouping and Model Preparation
[0081] Fifty 6-7 week old SPF male SD rats with a body weight of 180-200g were selected. After 7 days of adaptive feeding, the rats were randomly divided into a blank group (NC), a model group (Mode1), a low-dose embodiment 1 group (EG-L), a high-dose embodiment 1 group (EG-H) and a positive drug group (PC), with 10 rats in each group. Except for the blank group (NC), the rats in the other groups were all given chronic restraint stress plus senna leaf gavage to establish a diarrhea-type irritable bowel syndrome rat model. On the 1st to 7th day of the experiment, 10g / kg of senna leaf water was gavaged, once in the morning and once in the evening. After gavage of senna leaf water in the morning, the shoulders, forelimbs and chest and abdomen of the rats were restrained with medical elastic bandages to restrict them from scratching their head and face with their forelimbs, but their activities were not restricted. Each rat was kept on a regular basis for 2h every day, and they were free to eat and drink during this period.
[0082] 2. Medication intervention
[0083] Intervention began on the 7th day: the blank group and the model group were given sterile pure water 10 g / kg by gavage; the PC group was given pinaverium bromide suspension 13.5 mg / kg by gavage, the EG-L group was given a low dose of the composition of Example 1 8.55 g / kg by gavage, and the EG-H group was given a high dose of the composition of Example 1 17.1 g / kg by gavage, once a day.
[0084] 3. Model evaluation and efficacy assessment
[0085] (1) Appearance and mental state: observe the mental state, grasping stress, perianal contamination and hair condition of rats before and after modeling and treatment;
[0086] (2) Diarrhea: The stool characteristics of rats before and after treatment were observed. The stool of rats in each group before and after treatment was collected. The weight of fresh feces was weighed with a thousandth electronic balance, and then placed in an oven to dry to constant weight and then weighed with a thousandth electronic balance. The water content of feces of rats in each group was calculated and compared according to the formula: feces water content (mass %) = (fresh feces weight - dried feces weight) / fresh feces weight × 100%;
[0087] (3) Abdominal pain (visceral sensitivity): The abdominal withdrawal reflex (AWR) score was assessed by colorectal dilation with water injected into the enteral catheter before and after treatment, and the volume of water injected into the balloon at the AWR threshold of 3 points was compared.
[0088] (4) Colon histological staining: Colon specimens were fixed in 4% paraformaldehyde, embedded, and sliced. Colon hematoxylin-eosin (HE) staining, tissue sections were stained with Alcian blue-periodic acid Schiff (AB-PAS), and colon immunohistochemistry (IHC) staining were performed.
[0089] (5) Determination of colon mRNA expression level: Real-time fluorescence quantitative PCR (qRT-PCR) was used to detect the expression of colon Claudin-1, Qccludim, and Z0-1
[0090] 4. Experimental Results
[0091] (1) Comparison of general conditions of rats in each group after treatment
[0092] After modeling, the body weight of the model rats was significantly lower than that of the blank group rats (P<0.0001). After treatment, the body weight of the rats in each modeling group was still lower than that of the blank group (P<0.0001). The body weight of the rats increased significantly after treatment with the high-dose pharmaceutical composition of Example 1 (P<0.01). After modeling, the model rats were in poor spirits, slightly slow in reaction, had loose feces, and their hair was contaminated by loose feces. The above symptoms of the rats were improved after treatment with the high- and low-dose pharmaceutical compositions of Example 1. See Table 1.
[0093] Table 1 Comparison of body weight of rats in each group before and after treatment ( n=8)
[0094] Group Body weight before modeling (g) Body weight before administration (g) Body weight after 1 week of administration (g) Blank Group 216.70±8.89 276.63±10.62 330.85±11.35 Model Group 218.66±9.20 209.10±17.33* 247.79±12.29* EG-L group 215.90±8.64 207.59±24.86* 258.73±13.59 EG-H group 213.85±9.81 210.55±23.00* 267.24±10.30# PC Group 210.73±8.81 195.81±19.06* 248.74±7.56
[0095] Note: Compared with the blank group, *P<0.0001; compared with the model group, #P<0.01.
[0096] (2) Comparison of fecal water content in rats before and after treatment
[0097] After modeling, the fecal water content of all modeling rats increased significantly (P<0.0001), indicating that the modeling was successful. After treatment, compared with the model group, the fecal water content of the rats in the EG-H group was significantly reduced (P<0.05), indicating that the high-dose pharmaceutical composition of Example 1 can improve the diarrhea of rats with diarrhea-type irritable bowel syndrome. See Table 2.
[0098] Table 2 Comparison of fecal water content of rats in each group before and after treatment ( n=8)
[0099] Group Water content on the 7th day of modeling (%) Water content on the 7th day of treatment (%) Blank Group 59.76±3.73 61.95±5.66 Model Group 86.02±2.21* 79.61±5.31* EG-L group 86.13±2.35* 75.06±4.92 EG-H group 85.98±2.19* 74.90±3.07# PC Group 86.65±1.19* 80.10±3.18
[0100] Note: Compared with the blank group, *P<0.0001; compared with the model group, #P<0.05.
[0101] (3) Comparison of pain thresholds of colorectal distension in rats in each group before and after treatment
[0102] After modeling, the pain threshold intensity of colorectal distension in all model rats decreased significantly (P<0.0001). After treatment, the threshold intensity of rats in the EG-H group was significantly higher than that in the model group (P<0.001), indicating that the high-dose pharmaceutical composition of Example 1 can improve visceral hypersensitivity in rats with diarrhea-type irritable bowel syndrome. See Table 3.
[0103] Table 3 Comparison of pain threshold of colorectal distension in rats in each group before and after treatment ( n=8)
[0104] Group Balloon water injection volume before treatment / ml Balloon water injection volume after treatment / ml Blank Group 1.08±0.09 1.11±0.09 Model Group 0.72±0.08* 0.75±0.09* EG-L group 0.69±0.06* 0.83±0.04 EG-H group 0.70±0.04* 0.91±0.05# PC Group 0.68±0.04* 0.77±0.04
[0105] Note: Compared with the blank group, *P<0.0001; compared with the model group, #P<0.001.
[0106] (4) Comparison of colon pathology of rats in each group
[0107] HE staining of rat colon tissue after modeling showed a significant increase in intestinal secretion, with a large amount of cell debris in the cavity (black arrows), accompanied by inflammatory cell infiltration in the lamina propria (red arrows). After treatment with the pharmaceutical composition of Example 1 and pinaverium bromide, intestinal secretion decreased and inflammatory cell infiltration in the lamina propria decreased. AB-PAS staining showed an increase in intestinal mucus secretion in the model rats (black arrows), which was mainly a mixed mucus of purple, less acidic and blue. After treatment with the pharmaceutical composition of Example 1 and pinaverium bromide, intestinal secretion decreased, especially after treatment with a high dose of the pharmaceutical composition of Example 1, the mixed mucus of rats decreased significantly. This shows that the pharmaceutical composition of Example 1 can reduce intestinal mucus secretion and change the mucus composition of rats with diarrhea-predominant irritable bowel syndrome. See Figure 1 , Figure 2 .
[0108] In summary, the pharmaceutical composition of the present invention has a precise formula, can effectively treat diarrhea-type irritable bowel syndrome, provides an option for clinical treatment of the disease, and has good application prospects.
Claims
1. A Chinese medicine composition for treating diarrhea-type irritable bowel syndrome, Features: It is a preparation made from raw materials in the following weight ratio: 6-20 parts of cinnamon twig, 10-24 parts of curcuma, 6-25 parts of atractylodes, 6-25 parts of dried ginger, 6-21 parts of cinnamon, 12-22 parts of fennel, 10-20 parts of poria, 3-25 parts of pinellia, 6-20 parts of tangerine peel, 10-25 parts of evodia rutaecarpa, 12-24 parts of hawthorn, 12-20 parts of magnolia officinalis, and 3-10 parts of licorice.
2. The Chinese medicine composition for treating diarrhea-type irritable bowel syndrome according to claim 1, Features: It is a preparation made from raw materials in the following weight ratio: 12-18 parts of cinnamon twigs, 12-18 parts of curcuma, 12-18 parts of atractylodes, 12-18 parts of dried ginger, 8-12 parts of cinnamon, 12-18 parts of fennel, 12-18 parts of poria, 12-18 parts of pinellia, 12-18 parts of tangerine peel, 8-12 parts of evodia rutaecarpa, 16-24 parts of hawthorn, 8-12 parts of magnolia officinalis, and 8-12 parts of liquorice.
3. The Chinese medicine composition for treating diarrhea-type irritable bowel syndrome according to claim 2, Features: It is a preparation made from raw materials in the following weight ratio: 15 parts of cinnamon twigs, 15 parts of curcuma, 15 parts of atractylodes, 15 parts of dried ginger, 10 parts of cinnamon bark, 15 parts of fennel, 15 parts of poria, 15 parts of pinellia, 15 parts of tangerine peel, 10 parts of evodia rutaecarpa, 20 parts of hawthorn, 10 parts of magnolia officinalis, and 10 parts of liquorice.
4. The Chinese medicine composition for treating diarrhea-type irritable bowel syndrome according to any one of claims 1 to 3, Features: The pinellia is French pinellia; the hawthorn is raw hawthorn; and the licorice is roasted licorice.
5. The Chinese medicine composition for treating diarrhea-type irritable bowel syndrome according to any one of claims 1 to 4, Features: The invention is prepared from the raw drug powder, water or organic solvent extract of the raw drug in the weight ratio as active ingredients, and pharmaceutically acceptable auxiliary materials or auxiliary ingredients to prepare a commonly used oral preparation in medicine.
6. The Chinese medicine composition for treating diarrhea-type irritable bowel syndrome according to claim 5, Features: The oral preparations are decoctions, oral liquids, granules, capsules, tablets, and powders.
7. A method for preparing the Chinese medicine composition for treating diarrhea-type irritable bowel syndrome according to any one of claims 1 to 6, Features: It includes the following steps: (1) Weigh each API according to weight ratio; (2) The raw material drug is directly powdered, or the raw material drug is decocted with water or extracted with an organic solvent, the extract is concentrated, and then pharmaceutically acceptable excipients are added to prepare a preparation.
8. Use of the Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a medicament for treating diarrhea-predominant irritable bowel syndrome.
9. Use of the Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a medicament for treating diarrhea due to liver depression and spleen deficiency syndrome.
10. The use according to claim 9, Features: The medicine has the functions of supporting yang, warming the body, soothing the liver and strengthening the spleen.
Citation Information
Patent Citations
Plaster for treating chronic gastroenteritis
CN101642550A
Traditional Chinese medicine composition for preventing and treating diarrhea and application of traditional Chinese medicine composition
CN104013756A
